NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

TransMedics Group, Inc. (TMDX) Stock Analysis

TransMedics Group, Inc. (TMDX) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

TMDX

$89.98

+$3.00 (+3.45%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TMDX with… →

TMDX Key Statistics

As of Sep 4, 2026
Trading
Open
$84.63
Previous Close
$86.98
Day's Range
83.61–90.11
52-Week Range
60.11–156.00
Volume
542.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.88
Valuation
Market Cap
$3.12B
P/E Ratio
23.31
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
39.03
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.70
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.67
EPS (ttm)Profit attributable to each share over the last twelve months.
3.86
Financials (FY)
Revenue (FY)
$605.49M+37.13%
Net Income (FY)
$190.29M+436.58%
Profit marginThe share of revenue left as profit after all costs and taxes.
22.69%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
34.68M
1-Year Return
−13.52%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
942.63K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TMDX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−26.03%
2025+95.11%
2024−21.01%
2023+27.88%
2022+222.13%
2021−3.72%
2020+4.68%
2019 (partial year)−14.98%

As of September 4, 2026.

TMDX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$605.49M$190.29M31.4%
2024$441.54M$35.46M8.0%
2023$241.62M−$25.03M−10.4%
2022$93.46M−$36.23M−38.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$605.49M$362.81M$108.58M$190.29M31.4%
2024$441.54M$262.08M$37.50M$35.46M8.0%
2023$241.62M$154.09M−$28.73M−$25.03M−10.4%
2022$93.46M$65.27M−$31.44M−$36.23M−38.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TMDX Valuation vs Medical Devices Median

Median of 151 stocks
MetricTMDXMedical Devices medianvs median
P/E23.3126.8013% below
P/S ratio4.672.9857% above
Profit margin22.69%−1.69%24.4 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

TransMedics Group, Inc. (TMDX) is capitalised at $3.12B on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 898 employees.

The 52-week range on file runs from $60.11 to $156.00. TMDX last closed at $89.98 on September 4, 2026. That is +$3.00 (+3.45%) against the previous close. The latest close sits 49.7% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $605.49M. Against the prior fiscal year total of $441.54M, that is a change of +37.13%. The same year closed with net income of $190.29M. That is +436.58% against the prior fiscal year. The reported profit margin is 22.69%. That is 24.4 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to 3.86.

Across the 4 fiscal years on file, revenue moves from $93.46M in 2022 to $605.49M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 23.31. That is 13.02% below the Medical Devices median of 26.8. The forward P/E on file is 39.03. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.7. Measured against sales, the shares trade at 4.67 times revenue. On price-to-sales that is 56.83% above the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.88. Daily returns over the trailing 7 years annualize to a volatility of 71.76%. Over the trailing twelve months the price has returned −13.52%. Measured over 5 years, that is +22.46% a year compounded.

Growth & Income

No dividend is on file for TMDX.

The strongest complete calendar year on file is 2022 at +222.13%; the weakest is 2024 at −21.01%. Of the 6 complete calendar years on file, 4 finished higher. 2026 is still running; the price is −26.03% year to date.

Peer Comparison

TransMedics Group, Inc. (TMDX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TransMedics Group, Inc. TMDX $3.12B 23.3
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. TransMedics Group, Inc. trades at a P/E of 23.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About TransMedics Group, Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Visit website →